Planned share sale by Exelixis (NASDAQ: EXEL) director Wyszomierski

Rhea-AI Filing Summary

EXELIXIS, INC. director Jack L. Wyszomierski reported an open-market sale of 3,925 shares of common stock at $50.55 per share. The transaction was executed on June 1, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, he directly holds 284,384 shares of Exelixis common stock, and the filing notes an additional 8,367 shares that will be delivered upon vesting of restricted stock units.

Insights

Equity markets and insider-transactions analyst

Small, pre-planned stock sale by Exelixis director under Rule 10b5-1.

Director Jack L. Wyszomierski sold 3,925 shares of Exelixis common stock at $50.55 per share in an open-market transaction. The sale used a Rule 10b5-1 trading plan, indicating the trade was scheduled in advance rather than timed discretionarily.

After the sale, he directly holds 284,384 common shares, and the filing notes 8,367 additional shares tied to RSU awards that will vest later. With no derivative positions reported and a sizeable remaining equity stake, this appears to be a routine liquidity event rather than a major change in ownership posture.

Insider Trade Summary 10b5-1

Net Seller: 3,925 shares ($198,409)

Net Sell 1 txn

Insider WYSZOMIERSKI JACK L

Role null

Sold 3,925 shs ($198K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,925	$50.55	$198K

Holdings After Transaction: Common Stock — 284,384 shares (Direct, null)

Footnotes (1)

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025. Includes 8,367 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

Key Figures

Shares sold: 3,925 shares Sale price: $50.55 per share Shares held after sale: 284,384 shares +2 more

5 metrics

Shares sold 3,925 shares Open-market sale on June 1, 2026

Sale price $50.55 per share Price received for common stock sold

Shares held after sale 284,384 shares Direct common stock holdings post-transaction

RSUs outstanding 8,367 units Restricted stock units that will convert into common shares upon vesting

Rule 10b5-1 plan adoption date November 19, 2025 Date the pre-planned trading arrangement was adopted

Key Terms

Rule 10b5-1 trading plan, restricted stock units ("RSUs"), Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units ("RSUs") financial

"Includes 8,367 shares ... that will be issued ... upon vesting of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Common Stock financial

"Includes 8,367 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued..."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WYSZOMIERSKI JACK L

(Last) (First) (Middle)

C/O EXELIXIS, INC.

1851 HARBOR BAY PARKWAY

(Street)

ALAMEDA CALIFORNIA 94502

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXELIXIS, INC. [ EXEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		3,925	D	$50.55	284,384(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

2. Includes 8,367 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

Remarks:

	/s/ Nina Ayer, Attorney in Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did EXEL director Jack L. Wyszomierski report?

Director Jack L. Wyszomierski reported selling 3,925 shares of Exelixis common stock. The shares were sold in an open-market transaction at a price of $50.55 per share, according to the Form 4 insider filing for EXEL.

Was the EXEL insider sale by Jack L. Wyszomierski pre-planned under Rule 10b5-1?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan. That plan was adopted by Jack L. Wyszomierski on November 19, 2025, indicating the trades were scheduled in advance rather than timed opportunistically.

How many EXEL shares does Jack L. Wyszomierski hold after this Form 4 sale?

After the reported sale, Jack L. Wyszomierski directly holds 284,384 shares of Exelixis common stock. The Form 4 also notes 8,367 additional shares that will be issued to him upon vesting of his restricted stock units.

What price did EXEL director Jack L. Wyszomierski receive for the sold shares?

He received $50.55 per share for the 3,925 Exelixis common shares sold. This transaction price is explicitly disclosed in the Form 4, which characterizes the trade as an open-market sale of the company’s common stock.

Does Jack L. Wyszomierski have Exelixis RSUs in addition to common shares?

Yes. The Form 4 footnotes state he has 8,367 Exelixis restricted stock units outstanding. Each RSU is economically equivalent to one share of common stock and will convert into shares as the awards vest over time.